[Corrigendum] lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma
Affiliations: Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi 980‑8575, Japan, Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi 980‑8575, Japan, Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980‑8575, Japan, Department of Pathology, Tohoku University Hospital, Sendai, Miyagi 980‑8574, Japan
- Published online on: August 2, 2021 https://doi.org/10.3892/ol.2021.12959
- Article Number: 698
Copyright : © Yamada et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Oncol Lett 21: Article no. [Related article:] 455, 2021; DOI: 10.3892/ol.2021.12716
Subsequently to the publication of the above paper, the authors realized that the layouts of Tables I and III had been presented incorrectly, and that they had overlooking acknowledging researchers who had provided them with the cell lines in the Acknowledgements section of the paper.
Summary of patient/tumor characteristics and treatment outcomes for 23 patients/tumors analyzed via microarray analyses.
Consequently, the correctly organized versions of Tables I and 3 are shown on the subsequent pages. Concerning the oversight with the Acknowledgements section, this section of the declarations should be changed to the following (added text is highlighted in bold):
The authors would like to thank Ms Hiromi Nakano, Ms Noriko Takenaga and Ms Nobuko Saeki (Institute of Development, Aging and Cancer, Tohoku University) for their technical assistance. The authors would also like to sincerely thank Dr Mikio Masuzawa (School of Allied Health Science, Kitasato University), Dr Lan Kluwe (Laboratory for Tumor Genetics, University Medical Center Hamburg-Eppendorf), Dr Michiyuki Hakozaki (Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine), Dr Mikiko Aoki and Dr Kazuki Nabeshima (Department of Pathology, Fukuoka University School of Medicine) for providing the cell lines.
Note that the above errors did not affect the results or conclusions reported in this paper, and all the authors agree with this corrigendum. The authors thank the editor of Oncology Letters for presenting them with the opportunity of publishing this Corrigendum and apologize to the readership of the journal for any inconvenience caused.